Stay ahead of developments in federal and state health care law, regulation and transactions with timely, expert news and analysis.
By John Aquino
May 26 — Qiagen's GeneReader DNA sequencer infringes Illumina's patent, Illumina alleged in a May 24 federal district court complaint ( Illumina, Inc. v. QIAGEN, N.V., N.D. Cal., No. 3:16-cv-02788, filed 5/24/16 ).
The complaint filed in the U.S. District Court for the Northern District of California is the latest volley in the battle between these two competitors in the global gene sequencing market, which Illumina's then-chief executive officer said in January is at least a $20 billion market opportunity (10 LSLR 02, 1/22/16).
Intelligent Bio-Systems, a Qiagen subsidiary, challenged the validity of the same patent at issue in the present litigation before the Patent and Trademark Office's Patent Trial and Appeal Board, but the board ruled Feb. 11 that Qiagen hadn't established invalidity. On May 9, on Intelligent Bio-Systems' appeal, the U.S. Court of Appeals for the Federal Circuit upheld the PTAB's judgment (10 LSLR 10, 5/13/16).
With the Federal Circuit's judgment in its pocket, Illumina alleged in the Northern District of California that Qiagen, Intelligent Bio-Systems and other Qiagen subsidiaries infringed Illumina's U.S. Patent No. 7,566,537 (“Labelled Nucleotides,” issued July 28, 2009).
Illumina is based in San Diego. Qiagen is based in Hilden, Germany, and has U.S. offices in Germantown, Md.
The '537 patent covers methods of labeling a nucleic acid molecule with a non-natural, labeled nucleotide.
It demonstrates sequencing by synthesis (SBS), a process used to identify the sequence of nucleotides in DNA by synthesizing a single strand using nucleotides that complement the nucleotides in a sample single strand of DNA.
In the complaint, Illumina referenced the brochure for the GeneReader and its product description on Qiagen's Web page. Both describe the GeneReader's reliance on an SBS technology that “involves a 3 step process: extend, measure, and cleave.”
Illumina alleged that Qiagen's GeneReader infringes the '537 patent directly and that Qiagen and its subsidiaries have induced infringement and contributed to the infringement by others.
Illumina asked the court for an order stopping Qiagen and its subsidiaries from infringing the patent, damages, a declaration that the infringement was willful and a consequent trebling of the damages, a declaration that the case is exceptional and a subsequent award of its attorneys' fees and costs.
The complaint was filed by Weil, Gotshal & Manges LLP, Redwood Shores, Calif.
A Qiagen spokeswoman didn't immediately respond to Bloomberg BNA's request for comment.
To contact the reporter on this story: John T. Aquino in Washington at email@example.com
To contact the editor responsible for this story: Randy Kubetin at firstname.lastname@example.org
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)